What is Kallyope?
Headquartered at the Alexandria Center® for Life Science in New York City, Kallyope is a pioneering biotechnology company dedicated to discovering and developing novel therapeutics targeting the complex interplay of the gut-brain axis. The company leverages a multidisciplinary approach, integrating cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics. This comprehensive strategy aims to deepen the understanding of gut-brain biology, paving the way for transformative treatments designed to enhance human health.
How much funding has Kallyope raised?
Kallyope has raised a total of $486.1M across 5 funding rounds:
Private Equity
$28.1M
Series A
$44M
Series B
$66M
Series C
$112M
Series D
$236M
Private Equity (2015): $28.1M, investors not publicly disclosed
Series A (2015): $44M led by Lux Capital, The Column Group, Alexandria Venture, Illumina Inc, and Polaris Partners
Series B (2018): $66M supported by Alexandria, Two Sigma Ventures, Illumina Ventures, EUCLIDEAN CAPITAL, Polaris Partners, The Column Group, and Lux Capital
Series C (2020): $112M featuring Casdin Capital , LLC, Greenspring Associates Inc, Alexandria Venture Investments, Polaris Partners, The Column Group, Lux Capital, Bill Gates, Two Sigma Ventures, Illumina Ventures, and Euclidean Capital
Series D (2022): $236M backed by Mubadala and The Column Group
Key Investors in Kallyope
Mubadala
Mubadala is a global investment company based in Abu Dhabi, United Arab Emirates, established in October 2002 with a mandate to generate sustainable financial returns and contribute to the diversification of the global economy.
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, supporting companies from early-stage technology platforms to later-stage programs with a history of significant returns.
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, including biotechnology, from seed through IPO.
What's next for Kallyope?
With its recent major strategic investment, Kallyope is poised to accelerate its research and development pipeline. The company's focus on the gut-brain axis, a rapidly evolving field in neuroscience and gastroenterology, suggests a strategic direction towards addressing unmet medical needs. Future endeavors will likely involve advancing preclinical and clinical programs, further validating its therapeutic targets, and potentially forging strategic partnerships to bring its innovative treatments to market. The substantial capital raised indicates confidence in Kallyope's scientific approach and its potential to deliver significant advancements in human health.
See full Kallyope company page
